NRX Pharmaceuticals, Inc. (NRXP) company profile
Close on Nov 17, 2026Market cap $106.08MP/E –Yield –
About NRX Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that develops and distributes novel therapeutics for central nervous system disorders. Through its operating subsidiary, NeuroRx, Inc., the company focuses on treatments for conditions such as suicidal depression, chronic pain, post-traumatic stress disorder, and schizophrenia. Its lead drug candidates include preservative-free ketamine formulations (NRX-100 and KETAFREE™) and NRX-101, an oral combination therapy targeting neuroplasticity pathways. In addition, NRx operates a medical services segment through its majority-owned subsidiary, HOPE Therapeutics, Inc., which delivers interventional psychiatric care using neuromodulatory devices, neuroplastic drugs, digital therapeutics, and hyperbaric therapy. Its primary end customers are patients suffering from severe psychiatric and neurological conditions.
The company operates five clinical facilities in Florida, with clinics in Naples, Fort Myers, Sarasota, and West Palm Beach, and is developing additional sites in Massachusetts and Colorado. As of December 31, 2025, NRx employed approximately 29 full-time personnel. The provided text does not disclose the location of the company's headquarters.
Summary of the business section of NRX Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- NRX Pharmaceuticals, Inc.
- Founded
- 2018
- Headquarters
- Wilmington, DE
- Address
- 1201 Orange Street, Suite 600 19801
- Phone
- (484) 254-6134
- Website
- nrxpharma.com
- Employees
- 29, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Weinberg & Company P.A., Los Angeles, CA
Stock & identifiers
- Ticker
- NRXP
- Exchange
- Nasdaq
- IPO date
- Nov 21, 2017
- Shares outstanding
- 43M, Aug 14, 2026
- Public float
- $57.40M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-10 reverse, Apr 2, 2024; 49-for-4, Aug 16, 2021
- SEC CIK
- 1719406
- CUSIP
- 629444209
- ISIN
- US6294442099
- FIGI
- BBG00JCWDN63
- Share class FIGI
- BBG00JCWDNX3
- LEI
- 5493003FN4CLS0670T77
- EIN
- 82-2844431
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jonathan C. Javitt | CEO and Chairman, Director | 1,516,834 |
| Michael S. Abrams | Chief Financial Officer | – |
| Joseph Michael Casper | Chief Operating Officer | – |
| Patrick John Flynn | Director | 39,459 |
| Chaim Hurvitz | Director | 2,214,793 |
| Dennis McBride | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2024 PEO1 | $789.58K | $789.58K | $1.22M | $46 | – |
| FY2024 PEO2 | $0 | $0 | $1.22M | $46 | – |
| FY2024 PEO3 | – | $393.75K | $1.22M | $46 | – |
| FY2023 PEO1 | $500.00K | -$150.00K | $857.77K | $19 | – |
| FY2023 PEO2 | $0 | $0 | $857.77K | $19 | – |
| FY2023 PEO3 | – | $0 | $857.77K | $19 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2024
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Total | vs. prior year |
|---|---|---|---|---|
| Jonathan Javitt Chief Executive Officer, Chief Scientist and Chairman | $575.00K | $250.00K | $825.00K | +31% |
| Stephen Willard Former Chief Executive Officer | $395.83K | – | $395.83K | -21% |
| Michael Abrams Chief Financial Officer | $20.31K | – | $20.31K | – |
| Matthew Duffy Chief Business Officer | $338.00K | – | $338.00K | +113% |
| Richard Narido Former Chief Financial Officer | $435.03K | – | $435.03K | +46% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
SPAC offering
- Type
- SPAC (blank check) IPO of units
- Final prospectus filed
- Nov 21, 2017
- Offer price
- $10.00
- Securities offered
- 6,000,000
- Gross proceeds
- $60.00M
- Exchange
- Nasdaq
- First trading day
- Dec 1, 2017
- First-day close
- $9.08-9.2%
- Lock-up ends (est.)
- May 30, 2018
“Per Unit Total Public Offering Price $ 10.00 $ 60,000,000 Underwriting Discount (1) $ 0.25 $ 1,500,000 Proceeds to Big Rock Partners Acquisition Corp.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, the Company had approximately 29 full-time employees.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?